

Synergism of Buthionine Sulfoximine and Melphalan Against Neuroblastoma Cell Lines Derived After Disease Progression

Clarke P. Anderson, MD,^{1,2} Nino Keshelava, MD,¹ Noriko Satake, MD,¹
William H. Meek, BS,¹ and C. Patrick Reynolds, MD, PhD^{1,2,3*}

Background. Despite intensive-alkylator based regimens, >50% of patients with high-risk neuroblastoma (NB) die from recurrent disease that is probably due, in part, to acquired alkylator resistance. **Procedure.** Using buthionine sulfoximine (BSO)-mediated, glutathione (GSH) depletion to modulate melphalan (L-PAM) resistance, we examined six NB cell lines established after progressive disease following either standard chemotherapy, BSO/L-PAM therapy, or myeloablative therapy and autologous hematopoietic stem cell transplant (AHSCT). **Results.** Four of the six cell lines (three p53-nonfunctional and one p53-func-

tional) showed high-level L-PAM resistance. **Conclusions.** Fixed ratio analysis demonstrated BSO/L-PAM synergy (combination index >1) for all cell lines tested. In L-PAM-resistant cell lines, the minimal cytotoxicity observed for BSO combined with nonmyeloablative concentrations of L-PAM was markedly enhanced (>4 logs total cell kill) when BSO was combined with myeloablative concentrations of L-PAM. In alkylator-resistant NB, the optimal use of BSO may require dose escalation of L-PAM to levels requiring AHSCT. *Med. Pediatr. Oncol.* 35:659–662, 2000. © 2000 Wiley-Liss, Inc.

Key words: synergism; buthionine sulfoximine; melphalan; neuroblastoma cell lines; disease progression

INTRODUCTION

Most patients with stage 4 neuroblastoma (NB) diagnosed at age >1 year or stage 4 <1 year with *MYCN* amplification initially respond to therapy, but many ultimately succumb to recurrent disease that is refractory to chemotherapy [1–5]. Acquired alkylator resistance is one likely mechanism for treatment failure; current therapy of high-risk NB relies heavily on alkylating agents such as cyclophosphamide, carboplatin, cisplatin, and melphalan (L-PAM) [3,6,7]. We have previously shown that sustained resistance ($LC_{90} > 40 \mu\text{M}$) to the alkylating agent L-PAM occurs in a majority of cell lines established from patients who relapsed after myeloablative therapy that included intensive L-PAM (210 mg/m^2) during the preautologous hematopoietic stem cell transplant (AHSCT) conditioning [8,9]. However, insofar as high-level drug resistance in many NB may be due to a loss of p53 function [10], modulators of alkylator resistance will have to achieve cytotoxicity independent of p53 to be effective against such tumors.

Buthionine sulfoximine (BSO), a specific inhibitor of glutathione synthesis, depletes GSH and can reverse alkylator resistance [11–15]. BSO alone is highly cytotoxic for most NB cell lines in vitro and results in apoptosis following the generation of reactive oxygen species (ROS) [16]. Furthermore, BSO combined with L-PAM is synergistic against NB cell lines [17]. Nonmyeloablative trials of BSO and L-PAM in adults have shown the combination to be well-tolerated with reversible bone mar-

row suppression as the major clinical toxicity [18–21]. In this report, we show that BSO synergistically reverses L-PAM resistance in a group of highly L-PAM-resistant NB cell lines established after disease progression but only when L-PAM is escalated to levels achievable in the myeloablative setting.

MATERIALS AND METHODS

Cell Lines

Six NB cell lines established from patients who had progressive disease following standard chemotherapy (CHLA-20), BSO/LPAM therapy (CHLA-171), or my-

¹Division of Hematology-Oncology, Childrens Hospital Los Angeles, Los Angeles, California

²Department of Pediatrics, University of Southern California, Keck School of Medicine, Los Angeles, California

³Department of Pathology, University of Southern California, Keck School of Medicine, Los Angeles, California

Contract grant sponsor: Neil Bogart Memorial Laboratories of the T.J. Martell Foundation for Leukemia, Cancer, and AIDS Research; Contract grant sponsor: National Cancer Institute; Contract grant number: A82830; Contract grant number: CA82830; Contract grant sponsor: National Research Service Award; Contract grant number: 2 T32 CA 09659.

*Correspondence to: C.P. Reynolds, MD, PhD, Division of Hematology-Oncology, Childrens Hospital Los Angeles, 4650 Sunset Boulevard, MS 57, Los Angeles, CA 90027.
E-mail: preynolds@chla.usc.edu

TABLE I. Summary of Postprogressive Disease Neuroblastoma Cell Lines

	Post-AHSCT	p53 Functional	L-PAM LC ₉₀ (μM)	BSO LC ₉₀ (μM)	CI <1 at [AHSCT] ^a
CHLA-20	-	+	6	133	+
CHLA-171	-	-	42	509	+
CHLA-51	+	+	2	5	+
CHLA-79	+	+	4	10	+
CHLA-90	+	-	47	37	+
CHLA-134	+	-	52	939	+

^a[AHSCT], concentration L-PAM achievable in autologous hematopoietic stem cell transplantation.

Values represent mean ± standard error.

eloablative therapy and autologous hematopoietic stem cell transplant (post-AHSCT; CHLA-51, CHLA-79, CHLA-90, CHLA-134) were used for all studies in this report. Cell culture conditions, chemicals, digital image microscopy (DIMSCAN), glutathione levels, p53 function, and statistics were conducted as previously reported [8–10,16,17,22,23]. A single-drug dose-response software program was used to calculate Lethal Concentration (LC) values, with LC₉₀ defined as the respective concentration of drug required to kill 90% of cells tested [24–26]. Similarly, synergy between L-PAM and BSO was calculated using fixed ratio (BSO:L-PAM at 1:1 for CHLA-51, at 10:1 for all other cell lines) analysis [25–27], with synergy defined as a combination index (CI) <1. Synergy was also calculated by fixed ratio analysis to generate computer-simulated isobolograms (not shown) at values of LC₉₀ [24–27]. Dose combinations (L-PAM/BSO) for synergy testing were as follows: for CHLA-51, 0.6 μM/0.6 μM, 1.25 μM/1.25 μM, 2.5 μM/2.5 μM, 5 μM/5 μM, and 10 μM/10 μM; for all other cell lines, 3 μM/30 μM, 10 μM/100 μM, 20 μM/200 μM, 30 μM/300 μM, and 40 μM/400 μM.

RESULTS

Cytotoxicity Assays of BSO and L-PAM as Single Agents

The results of the cytotoxicity assays by DIMSCAN for L-PAM and BSO as single agents are summarized in Table I for all six cell lines. CHLA-171 and CHLA-134 were moderately resistant (LC₉₀ ≥509 μM) to L-(S,R) BSO. Among the three p53 functional cell lines, CHLA-51 was highly sensitive (LC₉₀ 2 μM) to L-PAM at non-myeloablative levels (≤3 μM achieved using 15 mg/m²), whereas CHLA-20 and CHLA-79 were intermediately L-PAM sensitive (4 μM and 6 μM, respectively). CHLA-171, CHLA-90, and CHLA-134 (all p53 non-functional) were highly resistant to L-PAM (LC₉₀ 47.0 μM ± 5 μM) at concentrations exceeding plasma levels obtained in the myeloablative setting [28,29].




Fig. 1. L-PAM dose response for CHLA-171. L-PAM as a single agent and L-PAM combined with a constant dose of 500 μM L-(S,R) BSO. Values represent mean ± standard error.

Cytotoxicity Assays of BSO Combined With L-PAM

Using a fixed ratio analysis, drug synergy (CI < 1) between BSO and L-PAM was observed for all cell lines at concentrations of L-PAM achievable in the AHSCT setting (Table I). In p53 functional, postprogressive disease cell lines (CHLA-20, CHLA-51, and CHLA-79), the combination of BSO and L-PAM was synergistic at L-PAM concentrations (≤3 μM) achievable in the non-myeloablative setting. Importantly, in highly L-PAM resistant, p53 nonfunctional cell lines (CHLA-90, CHLA-134, CHLA-171), drug synergy was not seen until the concentration of L-PAM was escalated to levels of L-PAM that are achievable only in the myeloablative setting (≥10 μM). The ability of L-PAM at myeloablative doses to synergize with BSO was particularly striking for CHLA-171 and CHLA-90 when 40 μM L-PAM was combined with 400 μM BSO, resulting in greater than a 4 log increase of cell kill compared to 40 μM of L-PAM alone. The dose response curve of L-PAM (0–40 μM) in combination with a constant level of 500 μM for the representative cell line CHLA-171 is shown in Figure 1.

Glutathione (GSH) Decreased by BSO

All cell lines were incubated in various concentrations of BSO (0–500 μM) for 24 hr, assayed for total GSH, and found to have depletion of GSH to <50% baseline. The concentrations of GSH (both baseline and following a 24 hr incubation with 500 μM BSO) in a representative L-PAM-resistant cell line (CHLA-171) are compared to the mean GSH under the same conditions for 10 previously reported [16] NB cell lines (Fig. 2). The baseline level of GSH in CHLA-171 was 0.49 ± 0.02 nmol/pg protein compared to a mean of 0.59 ± 0.08 nmol/pg




Fig. 2. Glutathione levels following BSO treatment. Values represent mean \pm standard error.

protein in the 10 cell lines, and GSH was depleted to 38% (CHLA-171) vs. 47% (mean of 10 cell lines).

DISCUSSION

Alkylating agents are integral to both induction therapy and myeloablative therapy for high-risk NB [1,4,6], and multidrug resistance associated with non-functional p53 is frequently found in NB cell lines established after disease progression [10]. Therefore, overcoming drug resistance may require p53-independent modulators of alkylator resistance. We studied six post-progressive disease NB cell lines that had a single-agent LC₉₀ for L-PAM ranging from 2 to 52 μ M compared to peak L-PAM plasma concentrations of 3.1 ± 0.8 μ M reported in our nonmyeloablative trial of BSO + L-PAM [30]. Data from the current report suggest that, for some NB cell lines, escalation of L-PAM to ≥ 10 μ M is needed to achieve multilog drug synergy. This suggests that nonmyeloablative L-PAM, both as a single agent and combined with BSO, would be ineffective for some patients with refractory disease. L-PAM resistance was not due to a failure of BSO to deplete GSH; there was no discernible difference in GSH (baseline and percentage depletion) between CHLA-171 and 10 other neuroblastoma cell lines. However, our data suggest that a multilog tumor cell kill might have occurred had BSO been used with doses of L-PAM achievable only in the myeloablative setting. Despite being obtained from a patient who relapsed after AHSCT, CHLA-51 was highly sensitive to both BSO and L-PAM as single agents. This is in contrast to the L-PAM resistance observed in other post-AHSCT neuroblastoma cell lines [9] and suggests that sensitivity to alkylating agents is retained in some patients who relapse after myeloablative therapy.

This current report shows, for some neuroblastoma

cell lines (including those lacking p53 function), a marked and sustained resistance to L-PAM exists, and BSO-mediated GSH depletion will not overcome the alkylator resistance that occurs frequently in NB cell lines established after AHSCT when L-PAM levels obtainable in the nonmyeloablative setting are used. However, the current data suggest that BSO may overcome high levels of L-PAM resistance (even in those cell lines lacking functional p53) if the L-PAM dose can be escalated to levels requiring hematopoietic stem cell support. Thus, if BSO/L-PAM is tolerable in the myeloablative setting, BSO may enhance the activity of L-PAM against drug-resistant NB and could improve outcome for NB patients undergoing myeloablative therapy after developing progressive disease. A clinical trial is in progress to determine the maximally tolerated dose of L-PAM given together with BSO and supported with AHSCT.

ACKNOWLEDGMENTS

This study was supported in part by NIH GCRC grant 3MO1ROO43-38 to the GCRC at Childrens Hospital Los Angeles.

REFERENCES

1. Reynolds CP, Seeger RC, Haskell CM, editors. Neuroblastoma. In: Cancer treatment. Philadelphia: W.B. Saunders; 2000.
2. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. *N Engl J Med* 1985;313:1111-1116.
3. Haase GM, Perez C, Atkinson JB. Current aspects of biology, risk assessment, and treatment of neuroblastoma. *Semin Surg Oncol* 1999;16:91-94.
4. Castleberry RP. Biology and treatment of neuroblastoma. *Pediatr Clin North Am* 1997;44:919-37.
5. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. *J Pediatr Hematol Oncol* 1999;21:181-189.
6. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. *N Engl J Med* 1999;341:1165-1173.
7. Cohn SL, Moss TJ, Hoover M, et al. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. *Bone Marrow Transplant* 1997;20:543-551.
8. Keshelava N, Seeger RC, Reynolds CP. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. *Eur J Cancer* 1997;33:2002-2006.
9. Keshelava N, Seeger RC, Groshen S, et al. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. *Cancer Res* 1998;58:5396-5405.
10. Keshelava N, Zuo JJ, Waidyaratne, N. Sitara, et al. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. *Med Pediatr Oncol* 2000;35:563-568.
11. Tew KD, Houghton PJ, Houghton JA. Modulation of glutathione. In: Tew KD, Houghton PJ, Houghton JA, editors. Preclinical and clinical modulation of anticancer drugs. Boca Raton, FL: CRC Press; 1993. p 13-77.

12. Hamilton TC, Winker MA, Louie KG, et al. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. *Biochem Pharmacol* 1985;34:2583–2586.
13. Green JA, Vistica DT, Young RC, et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. *Cancer Res* 1984;44:5427–5431.
14. Russo A, DeGraff W, Friedman N, Mitchell JB. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. *Cancer Res* 1986;46:2845–2848.
15. Siemann DW, Beyers KL. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. *Br J Cancer* 1993;68:1071–1079.
16. Anderson CP, Tsai JM, Meek WE, et al. Depletion of glutathione by buthionine sulfoximine is cytotoxic for human neuroblastoma cell lines via apoptosis. *Exp Cell Res* 1999;246:183–192.
17. Anderson CP, Tsai J, Chan W, et al. Buthionine sulphoximine alone and in combination with melphalan (L-pam) is highly cytotoxic for human neuroblastoma cell lines. *Eur J Cancer* 1997;33:2016–2019.
18. Bailey HH, Mulcahy RT, Tutsch KD, et al. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. *J Clin Oncol* 1994;12:194–205.
19. Bailey HH, Ripple G, Tutsch KD, et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. *JNCI* 1997;89:1789–1796.
20. O'Dwyer PJ, Hamilton TC, Young RC, et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. *JNCI* 1992;84:264–267.
21. Yao K, Godwin AK, Ozols RF, et al. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. *Cancer Res* 1993;53:3662–3666.
22. Frgala T, Proffitt RT, Reynolds CP. A novel 96-well plate cytotoxicity assay based on fluorescence digital imaging microscopy. *Proc Am Assoc Cancer Res* 1995;36:303.
23. Proffitt RT, Tran JV, Reynolds CP. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. *Cytometry* 1996;24:204–213.
24. Chou TC. Dose effect analysis with microcomputers [software program]. Cambridge, MA: Biosoft; 1988.
25. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. *JNCI* 1994;86:1517–1524.
26. Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. *J Biol Chem* 1977;252:6438–6442.
27. Chou T. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. *Mol Pharmacol* 1974;10:235–247.
28. Pinguet F, Martel P, Fabbro M, et al. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. *Anticancer Res* 1997;17:605–611.
29. Hersh MR, Ludden TM, Kuhn JG, Knight WA. Pharmacokinetics of high dose melphalan. *Invest New Drugs* 1983;1:331–334.
30. Anderson CP, Seeger RC, Matthey KK, et al. Buthionine sulfoximine (BSO) and mephalan (L-PAM) is active against recurrent neuroblastoma. *Med Pediatr Oncol* 1999;33:158.